Meeting
2015 ASCO Annual Meeting
LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
Authors
Heinz-Josef Lenz
Norris Comprehensive Cancer Center, Los Angeles, CA
Heinz-Josef Lenz , Josep Tabernero , Takayuki Yoshino , Zohra Oum'Hamed , Soetkin Vlassak , Mouna Sassi , Eric Van Cutsem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT02149108
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS3625)
DOI
10.1200/jco.2015.33.15_suppl.tps3625
Abstract #
TPS3625
Poster Bd #
115b
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment.
First Author: Heinz-Josef Lenz
Poster
2023 ASCO Gastrointestinal Cancers Symposium
INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).
First Author: Nick Pavlakis
Poster
2017 Gastrointestinal Cancers Symposium
Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study.
First Author: Heinz-Josef Lenz
Poster
2021 ASCO Annual Meeting
Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
First Author: Yoshitaka Honma